Denmark urges EU to tighten Russian visa restrictions after alleged assassination plot
Denmark has urged European Union countries to introduce tougher travel restrictions on Russian nationals following allegations that Moscow's in...
Rybelsus, an oral form of the GLP-1 drug semaglutide, has been discovered to provide similar cardiovascular benefits as the injectable forms of the drug.
Researchers presented this at the American College of Cardiology scientific meeting held in Chicago in March.
In a trial of 9,650 patients with type 2 diabetes, who had clogged heart arteries and/or chronic kidney disease, those taking Rybelsus were overall 14% less likely to experience heart-related death, heart attack or stroke than those who received a placebo after an average follow-up of four years.
Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes according to the New England Journal of Medicine.
The researchers saw a 26% reduction in non-fatal heart attacks with oral semaglutide and a 12% reduction in non-fatal strokes, both of which “are among the most common and devastating complications of diabetes,” study co author Dr. John Buse of the University of North Carolina School of Medicine said in a statement.
It is still unclear though the exact mechanism through which the drugs reduce cardiovascular risk is not known, however, their anti-inflammatory activity is thought to play a role.
“Semaglutide has been a mainstay of our efforts to reduce heart attack and stroke in people with diabetes,” Buse said. “Having an oral option to deliver this highly effective therapy is a big advance.”
Despite the resounding success of the drug manufactured alongside Ozempic, the injectable form by Pharma giant Novo Nordisk, the most common side effects mainly gastrointestinal problems such as nausea, diarrhea, constipation and gas remain.
European leaders backing Ukraine met in Berlin on Thursday 19 November and warned that no peace deal should be settled without them.
Three people have been killed and around 15 injured after Russian ballistic missiles struck three bridges over the Dnipro River in Kyiv, according to the Ukrainian capital’s mayor, Vitali Klitschko.
Azerbaijani President Ilham Aliyev met Vietnamese Prime Minister Le Minh Hung in Hanoi on 20 November, during a visit highlighting the longstanding friendship and growing strategic partnership between the two countries.
Britain and the European Union have reached an agreement to ease trade, expand opportunities for young people and deepen economic ties, in a major step towards rebuilding relations after Brexit.
Georgia has declared 22 November 2026 a national day of mourning following a deadly residential building collapse in the Kvemo Ponichala district of Tbilisi.
For the first time in more than a quarter of a century, the United States can no longer say it has eliminated measles as health experts warn the American outbreak reflects a collapse in trust in vaccines.
A new study in mice suggests the brain’s protective barrier does more than block harmful substances. It also delivers essential proteins from the body, a process that may break down early in Alzheimer’s disease and offer a new target for treatment.
Here's your AnewZ Daily Brief for the 5th of November, as health emergencies, humanitarian crises, political shifts, and cybersecurity threats put governments and essential services under pressure across the globe. Here are five stories worth your attention.
Kazakhstan plans to manufacture 494 types of medicines through eight major investment projects worth a combined $862 million, Health Minister Akmaral Alnazarova announced on 3 November, local media reported.
Dengue fever has killed more people in Bangladesh this year than in the whole of 2025, with October the deadliest month so far, data from Bangladesh's Health Ministry shows.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment